Description
Foracort (Budesonide + Formoterol) 200 Inhaler
Foracort is a combination inhaled medicine containing budesonide and formoterol. In regulatory and clinical literature, this drug pair is used as an inhaled corticosteroid and long-acting bronchodilator combination for airway diseases such as asthma and chronic obstructive pulmonary disease (COPD), depending on the specific product registration and country.
Active Ingredient and Medicine Class
The verified active ingredients are budesonide and formoterol. Budesonide is an inhaled corticosteroid that reduces airway inflammation. Formoterol is a long-acting beta2-adrenergic agonist (LABA) that relaxes airway smooth muscle and helps keep the airways open. Together, they form a fixed-dose combination inhaler designed to address both inflammation and bronchoconstriction.
Established Medical Uses
In official prescribing information for budesonide/formoterol combination inhalers, the medicine is indicated for maintenance treatment of asthma, and some products are also indicated for maintenance treatment of COPD in adults. The exact approved use depends on the local product label and presentation. This combination is not intended as a rescue treatment for sudden breathing difficulty.
How It Works
Budesonide works by suppressing inflammatory activity in the airways. It helps reduce the cell and mediator responses involved in airway swelling and irritation. Formoterol stimulates beta2 receptors in the lungs, which leads to relaxation of bronchial smooth muscle and improved airflow. Because the two components act through different mechanisms, the combination can provide both anti-inflammatory control and bronchodilation.
Important Safety Information
Budesonide/formoterol products are generally contraindicated in people with hypersensitivity to either active ingredient or to excipients in the inhaler. They are also not for the primary treatment of status asthmaticus or other acute episodes requiring intensive measures. LABA monotherapy has been associated with serious asthma-related risks, which is why formoterol is used here only in combination with an inhaled corticosteroid.
Important precautions include avoiding use as a reliever for acute symptoms, and avoiding concurrent use with other LABA-containing medicines because of the risk of excessive beta-agonist exposure. Clinically significant interactions may occur with strong CYP3A4 inhibitors, which can increase systemic corticosteroid exposure. Beta-blockers may reduce the effect of formoterol, and some adrenergic or QT-prolonging drugs may require caution because of cardiovascular effects. Inhaled corticosteroids may also be associated with reduced bone mineral density, ocular effects such as glaucoma or cataracts, and reduced growth velocity in children.
Possible Side Effects
Common adverse effects reported with budesonide/formoterol inhalers include throat irritation, hoarseness, cough, headache, and oral candidiasis. Some patients may also experience tremor, palpitations, or other beta-agonist effects. More serious reactions can include paradoxical bronchospasm, hypersensitivity reactions, adrenal suppression with excessive corticosteroid exposure, cardiovascular effects, and pneumonia risk in susceptible COPD patients.
Scientific Evidence
Human studies and reviews support the use of budesonide/formoterol as an established inhaled combination for asthma control, with evidence showing improved symptom control and fewer exacerbations when used appropriately in guideline-based regimens. In COPD, review data suggest that the combination can improve lung function and reduce exacerbations compared with either component alone in selected patients. Recent reviews also continue to evaluate the role of budesonide/formoterol in maintenance-and-reliever strategies for asthma.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It does not replace the official patient leaflet, local prescribing information, or assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration. SYMBICORT AEROSPHERE (budesonide and formoterol fumarate) Highlights of Prescribing Information. Official prescribing information. View official label
- Brian Lipworth et al. Budesonide/Formoterol or Budesonide/Albuterol as Anti-Inflammatory Reliever Therapy for Asthma. J Allergy Clin Immunol Pract, 2024. View scientific article
- David R Goldsmith et al. Budesonide/formoterol: a review of its use in asthma. Drugs, 2004. View scientific article
